TY - JOUR
T1 - Non-coding RNAs as therapeutic targets and biomarkers in ischaemic heart disease
AU - Caporali, Andrea
AU - Anwar, Maryam
AU - Devaux, Yvan
AU - Katare, Rajesh
AU - Martelli, Fabio
AU - Srivastava, Prashant Kumar
AU - Pedrazzini, Thierry
AU - Emanueli, Costanza
N1 - A.C. has received funding from the British Heart Foundation (Research Excellence Award 3 RE/18/5/34216 and project grant PG/22/10916). Y.D. has received funding from the EU Horizon 2020 project COVIRNA (grant agreement no. 101016072), the National Research Fund (grant no. 14/BM/8225223, C17/BM/11613033 and COVID-19/2020-1/14719577/miRCOVID), the Ministry of Higher Education and Research, and the Heart Foundation-Daniel Wagner of Luxembourg. R.K. has received funding from the Health Research Council New Zealand (grant no. 22/632). F.M. is supported by the Italian Ministry of Health projects Ricerca Corrente 2024 1.07.128, The Italian Cardiology Network IRCCS RCR-2022-23682288, RF-2019-12368521, POS T4 CAL.HUB.RIA cod. T4-AN-09, and by the Next Generation EU-NRRP M6C2 Inv. 2.1 PNRR-MAD-2022-12375790. F.M. has also received funding from Telethon Foundation (#4462 GGP19035A), by AFM-Telethon (#23054) and by Next Generation EU PNRR/2022/C9/MCID/I8 FibroThera. P.K.S. acknowledges the support of Integrated MRes/PhD 4-year studentship from a British Heart Foundation/National Heart and Lung Institute grant (FS/4yPhD/F/22/34178) and Diabetes UK grant (20/0006187). P.K.S. has also received funding from pharmaceutical companies F. Hoffmann-La Roche Ltd (Systems-PD, project ID: 5466496) and UCB Biopharma SPRL (EPINET 2). T.P. has received funding from the Swiss National Science Foundation: grants no. CRSII5_173738 and no. 31003A_182322. C.E. acknowledges the support of the following relevant awards from the British Heart Foundation: grants CH/15/1/3119, RG/20/9/35101, PG/22/11063, PG/23/11369 and RE/18/4/34215. Y.D., F.M., T.P. and C.E. were core members of the EU-CardioRNA COST Action CA17129 (www.cardiorna.eu). A.C., Y.D., F.M. and C.E. are also part of the AtheroNET COST Action CA21153. Both are funded by COST (European Cooperation in Science and Technology; www.cost.eu). We are grateful to J. Hill for English proofing the manuscript.
Publisher Copyright:
© Springer Nature Limited 2024.
PY - 2024/8
Y1 - 2024/8
N2 - The adult heart is a complex, multicellular organ that is subjected to a series of regulatory stimuli and circuits and has poor reparative potential. Despite progress in our understanding of disease mechanisms and in the quality of health care, ischaemic heart disease remains the leading cause of death globally, owing to adverse cardiac remodelling, leading to ischaemic cardiomyopathy and heart failure. Therapeutic targets are urgently required for the protection and repair of the ischaemic heart. Moreover, personalized clinical biomarkers are necessary for clinical diagnosis, medical management and to inform the individual response to treatment. Non-coding RNAs (ncRNAs) deeply influence cardiovascular functions and contribute to communication between cells in the cardiac microenvironment and between the heart and other organs. As such, ncRNAs are candidates for translation into clinical practice. However, ncRNA biology has not yet been completely deciphered, given that classes and modes of action have emerged only in the past 5 years. In this Review, we discuss the latest discoveries from basic research on ncRNAs and highlight both the clinical value and the challenges underscoring the translation of these molecules as biomarkers and therapeutic regulators of the processes contributing to the initiation, progression and potentially the prevention or resolution of ischaemic heart disease and heart failure.
AB - The adult heart is a complex, multicellular organ that is subjected to a series of regulatory stimuli and circuits and has poor reparative potential. Despite progress in our understanding of disease mechanisms and in the quality of health care, ischaemic heart disease remains the leading cause of death globally, owing to adverse cardiac remodelling, leading to ischaemic cardiomyopathy and heart failure. Therapeutic targets are urgently required for the protection and repair of the ischaemic heart. Moreover, personalized clinical biomarkers are necessary for clinical diagnosis, medical management and to inform the individual response to treatment. Non-coding RNAs (ncRNAs) deeply influence cardiovascular functions and contribute to communication between cells in the cardiac microenvironment and between the heart and other organs. As such, ncRNAs are candidates for translation into clinical practice. However, ncRNA biology has not yet been completely deciphered, given that classes and modes of action have emerged only in the past 5 years. In this Review, we discuss the latest discoveries from basic research on ncRNAs and highlight both the clinical value and the challenges underscoring the translation of these molecules as biomarkers and therapeutic regulators of the processes contributing to the initiation, progression and potentially the prevention or resolution of ischaemic heart disease and heart failure.
UR - http://www.scopus.com/inward/record.url?scp=85188097124&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/38499868
U2 - 10.1038/s41569-024-01001-5
DO - 10.1038/s41569-024-01001-5
M3 - Review article
C2 - 38499868
AN - SCOPUS:85188097124
SN - 1759-5002
VL - 21
SP - 556
EP - 573
JO - Nature Reviews Cardiology
JF - Nature Reviews Cardiology
IS - 8
ER -